Qiagen N.V. (QGEN)
Automate Your Wheel Strategy on QGEN
With Tiblio's Option Bot, you can configure your own wheel strategy including QGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QGEN
- Rev/Share 9.1716
- Book/Share 15.6055
- PB 2.9829
- Debt/Equity 0.4133
- CurrentRatio 3.3715
- ROIC 0.0157
- MktCap 10080681800.0
- FreeCF/Share 2.3037
- PFCF 20.0384
- PE 108.5171
- Debt/Assets 0.254
- DivYield 0.0284
- ROE 0.0269
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | QGEN | Redburn Atlantic | Buy | Neutral | -- | -- | April 4, 2025 |
| Downgrade | QGEN | Robert W. Baird | Outperform | Neutral | $52 | $42 | Feb. 19, 2025 |
| Downgrade | QGEN | Morgan Stanley | Overweight | Equal Weight | -- | $48 | Jan. 6, 2025 |
| Upgrade | QGEN | Jefferies | Hold | Buy | $42.5 | $54 | Dec. 10, 2024 |
| Downgrade | QGEN | HSBC Securities | Buy | Hold | -- | $49 | Oct. 17, 2024 |
News
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
Read More
QGEN Stock Rises in After Market Following Partnership With Incyte
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.
Read More
Should You Add QIAGEN Stock to Your Portfolio for Now?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Negative
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
Read More
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Read More
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Qiagen (QGEN) is a Strong Value Stock
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.
Read More
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (MRD) testing in clinical trials to support pharma co-development projects for companion diagnostics. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN's reach in MRD testing and cover solid tumors and hematological cancers.
Read More
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
BOULDER, Colo. , Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to develop and commercialize a kit-based version of Foresight's CLARITY™ assay, with the goal of enabling global in vitro diagnostic (IVD) and companion diagnostic (CDx) applications in lymphoma and other hematological malignancies.
Read More
QGEN Stock Might Gain Following New Partnership With ID Solutions
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.
Read More
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Qiagen (QGEN) is a Strong Value Stock
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Qiagen N.V. (NYSE:QGEN ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants John Gilardi - Vice President, Head of Corporate Communications & Investor Relations Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Doug Schenkel - Wolfe Research Patrick Donnelly - Citi Tycho Peterson - Jefferies Michael Ryskin - Bank of America Jan Koch - Deutsche Bank Jack Meehan - Nephron Research Dan Brennan - TD Cowen Catherine Schulte - Baird Matt Sykes - Goldman Sachs Casey Woodring - JPMorgan Operator Ladies and gentlemen, thank …
Read More
QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.
Read More
Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.47 per share a year ago.
Read More
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN's strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth. The Supervisory Boar.
Read More
Stay Ahead of the Game With Qiagen (QGEN) Q1 Earnings: Wall Street's Insights on Key Metrics
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Qiagen (QGEN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
QGEN or RGEN: Which Is the Better Value Stock Right Now?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?
Read More
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
Published: April 08, 2025 by: Business Wire
Sentiment: Neutral
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect.
Read More
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below.
Read More
About Qiagen N.V. (QGEN)
- IPO Date 1996-06-28
- Website https://www.qiagen.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Thierry Bernard
- Employees 5700